AACR 2022 - Flagship Biosciences

AACR 2022

Visit Flagship at AACR | Booth #1554 April 8-13, 2022

Stop by our booth to talk with us about how we can partner with you for end-to-end biomarker support, see our latest data from this year’s featured posters, and pick up a map of our favorite NOLA eateries.

Assay development and validation
Clinical trial support
Regulatory guidance
Our favorite New Orleans locales!

The Digital Pathology Advantage

Improve ROI, accelerate trials, and minimize budget impacts
Minimize recruitment costs and other clinical trial expenses
Discover cost benefits of Flagship’s image analysis platform

See the guide >>

Validated assays for spatial biology

View our validated IHC assays
See our IHC/CISH optimized assays
Learn our multiplex and custom panel options

See the assay list >>

Driving Your Biomarker Strategy: Facts by numbers

View our resume and history to learn why
Flagship is the premier partner for your study See the full list of spatial biology services that empower confident clinical decision making
See the benefits with a fully integrated team of scientists and pathologists

Download the fact >>

Check out our AACR22 posters that discuss how macrophage biomarkers CD68 and CD163 correlate with NSCLC and CRC patient survival

CRC

NSCLC

READY TO TAKE THE NEXT STEP?

Flagship carefully tracks our tissue to ensure we can analyze every assay and stay on schedule.

We are trying to bridge from the discovery stage to clinical development. Flagship's pathologists and scientists provide critical input and the company helps us organize and analyze an incredible amount of data. I highly recommend Flagship for its expertise and support for drug development projects.

During clinical trials, I interact with our manufacturing, legal, pre-clinical, and biomarker teams. Our Flagship project manager understands our tight timeline and ensures delivery of the data we need, when we need it.

We are pleased to partner with Flagship Biosciences to integrate their machine learning/AI tools to provide cancer marker detection.

Flagship’s image analysis experts are flexible and willing to work with us to develop projects that meet the changing needs of our clinical trials drug development.

Flagship has a high reputation as a supplier of advanced IHC services and their CAP-CLIA environment is a perfect complement to our own testing facilities.

The ease of leveraging Flagship’s powerful solution is yet another massive differentiator of the company. Clients need not have to change their existing workflows, investments in technology, or even the assays that they use.